Cancer immunotherapy: More is (much) better

Yosef Yarden, Michael Sela

Research output: Contribution to journalArticlepeer-review


Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.

Original languageEnglish
Pages (from-to)4030-4032
Number of pages3
JournalClinical Cancer Research
Issue number18
StatePublished - 15 Sep 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cancer immunotherapy: More is (much) better'. Together they form a unique fingerprint.

Cite this